Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31047535 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5754979 | 0.88 | ALDH1A1 (0.61) | MEN1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL18291244 | 0.84 | MAP4K4 (0.47) | MEN1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL4020520 | 0.82 | CYP1A2 (0.57) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4020924 | 0.80 | CYP1A2 (0.60) | MEN1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL2866512 | 0.78 | CYP1A2 (0.40) | MEN1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL13279548 | 0.78 | MAP4K4 (0.57) | MEN1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL14051230 | 0.77 | CNR2 (0.70) | MEN1NPC1RAB9AKMT2ACNR2 | |
| SCHEMBL611989 | 0.77 | HRH4 (0.51) | KMT2AALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL3723054 | 0.77 | BPTF (0.62) | ALDH1A1HTTKDM4EHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106008533-A | Cdk inhibitors | G1治疗公司 | 2016-10-12 | — | — | CN | claimed |
| US-12600726-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | disclosed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-117677387-A | Treatment of inflammatory diseases | 加拉帕戈斯股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117534670-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-4104385-A | Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates | STERLING DRUG INC. (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | MEN1 1365/4885NPC1 190/4885RAB9A 1049/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | MEN1 244/4885NPC1 1233/4885RAB9A 550/4885 |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | NAT1, POLM, PYGL | MEN1 4116/4885NPC1 640/4885RAB9A 2946/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | MEN1 4351/4885NPC1 4365/4885RAB9A 1663/4885 |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | F12, C1R, MRPL21 | MEN1 244/4885NPC1 1233/4885RAB9A 550/4885 |
| US-12600726-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM3, CHRM4, CHRM2 | MEN1 2196/4885NPC1 503/4885RAB9A 2745/4885 |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | MEN1 1551/4885NPC1 1352/4885RAB9A 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.